Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Diabetes Care|October 9, 2012
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, et al.
Diabetes Technology & Therapeutics|April 12, 2007
Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weightDiane Karl, Athena Philis-Tsimikas, Tamara Darsow, et al.
Translational Behavioral Medicine|March 22, 2014
Dulce Mothers: an intervention to reduce diabetes and cardiovascular risk in Latinas after gestational diabetesAthena Philis-Tsimikas, Addie L Fortmann, Sapna Dharkar-Surber, et al.
Diabetes Care|August 29, 2020
Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital SettingAddie L Fortmann, Samantha R Spierling Bagsic, Laura Talavera, et al.
The Lancet. Diabetes & Endocrinology|March 6, 2019
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trialBernard Zinman, Vaishali Bhosekar, Robert Busch, et al.
Health and Quality of Life Outcomes|May 4, 2018
When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigationJames Weatherall, William H Polonsky, Sally Lanar, et al.
Diabetes Research and Clinical Practice|October 5, 2024
Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1William Polonsky, Malik Benamar, Lisbeth Carstensen, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trialChantal Mathieu, Bruce W Bode, Edward Franek, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|February 2, 2019
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 TrialLouis Chaykin, Anuj Bhargava, Raymond de la Rosa, et al.
Drugs|August 13, 2025
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes ManagementAthena Philis-Tsimikas, Jens Aberle, Harpreet Bajaj, et al.
Pageof 10